Hard Empty Capsules: Prelim CVD Cash Deposit Rates Take Effect for 4 Countries
Suspension of liquidation and countervailing duty cash deposit requirements took effect March 31 for imports of hard empty capsules from Brazil (C-351-865), China (C-570-185), India (C-533-935) and Vietnam (C-552-848), after the Commerce Department found countervailable subsidization in preliminary determinations in its ongoing CVD investigations.
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
Commerce is also conducting concurrent antidumping duty investigations on hard empty capsules from Brazil, China, India and Vietnam, with Commerce's preliminary AD determinations currently due May 22.
CVD Suspension of Liquidation and Cash Deposit Requirements
Commerce will instruct CBP to suspend liquidation for CVD purposes for all entries of subject merchandise from Brazil, China, India and Vietnam that are entered, or withdrawn from warehouse, for consumption on or after March 31. It will require CVD cash deposits at the following rates:
Brazil
Company | CVD Rate |
---|---|
ACG do Brasil S.A | 4.94% |
All Others | 4.94% |
China
Company | CVD Rate |
---|---|
Jiangsu Lefan Capsule Co., Ltd | 3.45% |
Shanxi JC Biological Technology Co., Ltd | 8.53% |
All Others | 6.82% |
India
Company | CVD Rate |
---|---|
ACG Associated Capsules Private Limited; ACG Pam Pharma Technologies Private Limited; ACG Universal Capsules Private Limited | 9.95% |
All Others | 9.95% |
Vietnam
Company | CVD Rate |
---|---|
Suheung Vietnam Co., Ltd | 2.15% |
All Others | 2.15% |
(The period of investigation for Brazil, China and Vietnam is 01/01/23 - 12/31/23, and for India it's 04/01/23 - 03/31/24. See Commerce's notice for more information, including the scope (unchanged), suspension of liquidation, etc. See 2411200027 for a summary of the initiation of these CVD investigations, including deadlines and scope information.)